Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported that on August 3, 2026, its Board Compensation Committee granted non-qualified stock options to purchase an aggregate 84,000 shares of common stock to two newly hired employees under its 2022 Employment Inducement Incentive Award Plan.

The options were issued as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4), carry a $4.65 exercise price equal to the grant-date closing price, have a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.

Positive

• 84,000-share inducement options granted to support new employee hiring
• Options priced at $4.65, equal to grant-date Nasdaq closing price
• Four-year vesting schedule with 10-year term supports employee retention incentives

Negative

• Potential shareholder dilution of up to 84,000 additional shares if options are exercised

News Explained

The August 3 grant is complete as an option award, not an immediate stock issuance: it gives two new employees a conditional right to acquire 84,000 common shares, so existing ownership could be diluted only as the options vest and are exercised, subject to continued service.

Market Context

ZNTL's prior inducement-grant announcement covered 191,000 shares and was followed by a -0.75% 24-ho...

Analysis

ZNTL's prior inducement-grant announcement covered 191,000 shares and was followed by a -0.75% 24-hour reaction. That platform precedent frames the current grant, with moderate short positioning as a risk factor to monitor.

Key Figures

Inducement shares: 84,000 shares Recipients: two employees Exercise price: $4.65 per share +5 more

8 metrics

Inducement shares 84,000 shares Aggregate options granted to two newly hired employees

Recipients two employees Newly hired employees receiving stock options

Exercise price $4.65 per share Equal to the closing price on the grant date

Option term 10-year term Term of the granted stock options

Vesting period four years Overall vesting schedule

First-year vesting 25% Options vesting on the first anniversary

Remaining vesting 75% Vesting in equal monthly installments thereafter

Remaining vesting period three years Period for monthly vesting of the remaining options

Historical Context

5 past events · Latest: Jul 17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 17	ESMO presentation	Neutral	-2.0%	Announced planned ESMO presentations of ovarian-cancer program data and trial information
Jun 01	Inducement grants	Negative	-0.8%	Granted options covering 191,000 shares to two newly hired employees
May 27	Leadership appointments	Positive	+0.8%	Appointed Shannon Campbell to the board and Sarah Kelly as commercial-strategy SVP
May 21	Phase 1b clinical data	Positive	-1.9%	Reported MUIR trial activity including 39.1% ORR and 7.3-month median PFS
May 13	Investor conferences	Neutral	-4.4%	Announced management participation in multiple May and June investor conferences

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Four of the five recent announcements were followed by negative 24-hour price reactions, including the prior inducement-grant release.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), exercise price

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 84,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock options have an exercise price of $4.65 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on August 3, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 84,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $4.65 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​ 

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact: 
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

What inducement stock options did Zentalis Pharmaceuticals (ZNTL) grant on August 3, 2026?

Zentalis granted non-qualified stock options for 84,000 shares of common stock to two new employees. According to Zentalis, these were inducement awards under the 2022 Inducement Plan, designed to attract new hires under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Zentalis (ZNTL) inducement options granted in August 2026?

The inducement options have an exercise price of $4.65 per share. According to Zentalis, this price matches the closing price of its common stock on The Nasdaq Global Market on the August 3, 2026 grant date.

How do the Zentalis (ZNTL) August 2026 inducement options vest for new employees?

The options vest over four years, with 25% vesting after one year and 75% vesting monthly over three years. According to Zentalis, vesting is contingent on each employee’s continued service on the applicable vesting dates.

What is the term of the Zentalis Pharmaceuticals (ZNTL) inducement stock options granted in 2026?

The inducement stock options carry a 10-year term from the grant date. According to Zentalis, this term defines how long the option holders may exercise the awards, subject to vesting and continued employment conditions.

Under which plan and Nasdaq rule were the Zentalis (ZNTL) August 2026 inducement grants made?

The grants were made under the 2022 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to Zentalis, this plan is used exclusively for equity awards to new or returning employees as employment inducements.